Categorizing clinical response to mepolizumab for patients with chronic rhinosinusitis with nasal polyps: SYNAPSE trial
Year: 2025
Type: article
Abstract: Chronic rhinosinusitis with nasal polyps (CRSwNP) can substantially impact quality of life (QoL), and is often challenging to manage.1 First-line treatment for the management of CRSwNP involves intranasal corticosteroids (INCS), with short courses of systemic corticosteroids (SCS) for exacerbations, and sinus surgery for uncontrolled disease.2 Biologics targeting type 2 inflammation (e.g., dupilumab, omalizumab, and mepolizumab) have become a treatment option for refractory CRSwNP. With the advent of disease-modifying treatments such as biologics, control, defined as patients reporting no/low symptom levels, has increasingly become the treatment goal for CRSwNP.
Institutions: Guy's Hospital, St Thomas' Hospital, King's College London, Guy's and St Thomas' NHS Foundation Trust, King's College Hospital, University of Virginia Health System, University of Virginia, GlaxoSmithKline (United States), GlaxoSmithKline (United Kingdom), GlaxoSmithKline (Germany), GlaxoSmithKline (India), Old Dominion University
Language: English
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,400
Funder: GlaxoSmithKline
Award: G6246197190
OpenAlex ID: W4411449344